Logo image of BAYN.DE

BAYER AG-REG (BAYN.DE) Stock Fundamental Analysis

FRA:BAYN - Deutsche Boerse Ag - DE000BAY0017 - Common Stock - Currency: EUR

24.725  +0.05 (+0.22%)

Fundamental Rating

3

Overall BAYN gets a fundamental rating of 3 out of 10. We evaluated BAYN against 53 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of BAYN have multiple concerns. BAYN is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BAYN had positive earnings in the past year.
BAYN had a positive operating cash flow in the past year.
In multiple years BAYN reported negative net income over the last 5 years.
Each year in the past 5 years BAYN had a positive operating cash flow.
BAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFBAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

1.2 Ratios

BAYN has a Return On Assets of -2.30%. This is in the lower half of the industry: BAYN underperforms 66.04% of its industry peers.
BAYN has a Return On Equity of -8.00%. This is in the lower half of the industry: BAYN underperforms 66.04% of its industry peers.
Industry RankSector Rank
ROA -2.3%
ROE -8%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
BAYN.DE Yearly ROA, ROE, ROICBAYN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

In the last couple of years the Operating Margin of BAYN has declined.
With a Gross Margin value of 54.36%, BAYN is not doing good in the industry: 71.70% of the companies in the same industry are doing better.
BAYN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BAYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.36%
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
BAYN.DE Yearly Profit, Operating, Gross MarginsBAYN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

1

2. Health

2.1 Basic Checks

BAYN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BAYN has about the same amount of shares outstanding.
BAYN has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, BAYN has an improved debt to assets ratio.
BAYN.DE Yearly Shares OutstandingBAYN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
BAYN.DE Yearly Total Debt VS Total AssetsBAYN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

BAYN has an Altman-Z score of 0.80. This is a bad value and indicates that BAYN is not financially healthy and even has some risk of bankruptcy.
BAYN's Altman-Z score of 0.80 is on the low side compared to the rest of the industry. BAYN is outperformed by 66.04% of its industry peers.
BAYN has a debt to FCF ratio of 8.90. This is a slightly negative value and a sign of low solvency as BAYN would need 8.90 years to pay back of all of its debts.
The Debt to FCF ratio of BAYN (8.90) is worse than 60.38% of its industry peers.
A Debt/Equity ratio of 1.11 is on the high side and indicates that BAYN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.11, BAYN is doing worse than 64.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 8.9
Altman-Z 0.8
ROIC/WACCN/A
WACC5.98%
BAYN.DE Yearly LT Debt VS Equity VS FCFBAYN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

BAYN has a Current Ratio of 1.19. This is a normal value and indicates that BAYN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.19, BAYN is not doing good in the industry: 75.47% of the companies in the same industry are doing better.
BAYN has a Quick Ratio of 1.19. This is a bad value and indicates that BAYN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.72, BAYN is not doing good in the industry: 77.36% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.72
BAYN.DE Yearly Current Assets VS Current LiabilitesBAYN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

3

3. Growth

3.1 Past

BAYN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.72%.
BAYN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.27% yearly.
BAYN shows a decrease in Revenue. In the last year, the revenue decreased by -2.16%.
The Revenue has been growing slightly by 1.37% on average over the past years.
EPS 1Y (TTM)-24.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-11.7%
Revenue 1Y (TTM)-2.16%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-0.2%

3.2 Future

BAYN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.19% yearly.
Based on estimates for the next years, BAYN will show a small growth in Revenue. The Revenue will grow by 1.18% on average per year.
EPS Next Y-8.65%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
EPS Next 5Y1.19%
Revenue Next Year-0.13%
Revenue Next 2Y0.7%
Revenue Next 3Y1.06%
Revenue Next 5Y1.18%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BAYN.DE Yearly Revenue VS EstimatesBAYN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B 40B 50B
BAYN.DE Yearly EPS VS EstimatesBAYN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 5.24, the valuation of BAYN can be described as very cheap.
94.34% of the companies in the same industry are more expensive than BAYN, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.20. BAYN is valued rather cheaply when compared to this.
BAYN is valuated cheaply with a Price/Forward Earnings ratio of 5.01.
Based on the Price/Forward Earnings ratio, BAYN is valued cheaper than 96.23% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BAYN to the average of the S&P500 Index (22.13), we can say BAYN is valued rather cheaply.
Industry RankSector Rank
PE 5.24
Fwd PE 5.01
BAYN.DE Price Earnings VS Forward Price EarningsBAYN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BAYN indicates a rather cheap valuation: BAYN is cheaper than 90.57% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BAYN is valued cheaper than 98.11% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.29
EV/EBITDA 6.24
BAYN.DE Per share dataBAYN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.15%
EPS Next 3Y1.51%

More info and screens

0

5. Dividend

5.1 Amount

BAYN has a yearly dividend return of 0.46%, which is pretty low.
Compared to an average industry Dividend Yield of 3.05, BAYN is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.40, BAYN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.46%

5.2 History

The dividend of BAYN decreases each year by -45.34%.
Dividend Growth(5Y)-45.34%
Div Incr Years1
Div Non Decr Years3
BAYN.DE Yearly Dividends per shareBAYN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

The earnings of BAYN are negative and hence is the payout ratio. BAYN will probably not be able to sustain this dividend level.
DP-5.13%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
BAYN.DE Yearly Income VS Free CF VS DividendBAYN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

More info and screens

BAYER AG-REG

FRA:BAYN (5/29/2025, 5:35:15 PM)

24.725

+0.05 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners47.61%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.29B
Analysts67.59
Price Target27.5 (11.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.46%
Yearly Dividend0.13
Dividend Growth(5Y)-45.34%
DP-5.13%
Div Incr Years1
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.93%
Min EPS beat(2)-17.26%
Max EPS beat(2)3.41%
EPS beat(4)3
Avg EPS beat(4)0.78%
Min EPS beat(4)-17.26%
Max EPS beat(4)12.55%
EPS beat(8)5
Avg EPS beat(8)-3.08%
EPS beat(12)8
Avg EPS beat(12)-0.96%
EPS beat(16)12
Avg EPS beat(16)2.1%
Revenue beat(2)1
Avg Revenue beat(2)-0.82%
Min Revenue beat(2)-3.42%
Max Revenue beat(2)1.79%
Revenue beat(4)2
Avg Revenue beat(4)-1.4%
Min Revenue beat(4)-4%
Max Revenue beat(4)1.79%
Revenue beat(8)2
Avg Revenue beat(8)-2.97%
Revenue beat(12)5
Avg Revenue beat(12)-1.57%
Revenue beat(16)9
Avg Revenue beat(16)-0.6%
PT rev (1m)-0.3%
PT rev (3m)-0.64%
EPS NQ rev (1m)27.23%
EPS NQ rev (3m)-5.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.05%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)-2.78%
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)-0.25%
Valuation
Industry RankSector Rank
PE 5.24
Fwd PE 5.01
P/S 0.52
P/FCF 5.29
P/OCF 3.3
P/B 0.76
P/tB N/A
EV/EBITDA 6.24
EPS(TTM)4.72
EY19.09%
EPS(NY)4.93
Fwd EY19.96%
FCF(TTM)4.67
FCFY18.89%
OCF(TTM)7.5
OCFY30.32%
SpS47.44
BVpS32.48
TBVpS-20.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.3%
ROE -8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.36%
FCFM 9.84%
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)7.82%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
F-Score6
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 8.9
Debt/EBITDA 4.07
Cap/Depr 31.63%
Cap/Sales 5.96%
Interest Coverage N/A
Cash Conversion 84.55%
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 0.72
Altman-Z 0.8
F-Score6
WACC5.98%
ROIC/WACCN/A
Cap/Depr(3y)34.81%
Cap/Depr(5y)41.62%
Cap/Sales(3y)5.85%
Cap/Sales(5y)5.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-11.7%
EPS Next Y-8.65%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
EPS Next 5Y1.19%
Revenue 1Y (TTM)-2.16%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-0.2%
Revenue Next Year-0.13%
Revenue Next 2Y0.7%
Revenue Next 3Y1.06%
Revenue Next 5Y1.18%
EBIT growth 1Y-111.6%
EBIT growth 3Y-16.56%
EBIT growth 5Y-3.03%
EBIT Next Year63.3%
EBIT Next 3Y21.17%
EBIT Next 5Y9.38%
FCF growth 1Y93.91%
FCF growth 3Y22.16%
FCF growth 5Y-3.69%
OCF growth 1Y43.95%
OCF growth 3Y12.83%
OCF growth 5Y-2.09%